Genus PLC (GNS)

Industry Biotechnology


This stock can be held in an Investment ISA, SIPP and Investment Account
Sell

2,090.00p

Buy

2,095.00p

arrow-up30.00p (+1.45%)

Prices updated at 16 May 2025, 17:15 BST
| Prices minimum 15 mins delay
|
Prices in GBX

Genus PLC focusses on the healthcare sector. It specializes in providing genetic products intended for animals, which allow farmers to produce an enhanced quality of milk products.
Sector
Healthcare
Industry
Biotechnology
Chairman
Mr. Iain George Thomas Ferguson CBE
CEO
Mr. Jorgen Kokke
Most recent earnings
30 Jun 2024
Fiscal year end
30 Jun 2024
Employees
3,573
Head office
Matrix House
Basingstoke
United Kingdom
RG21 4DZ
mobile
+44 1256347100
letter
charlesr@buchanan.uk.com

Key personnel

Salary
Ms. Lesley Mary Samuel Knox OBE
Non-Executive Director, Senior Independent Director; Workforce Engagement Director
-
Mr. Iain George Thomas Ferguson CBE
Non-Executive Director, Chairman
-
Mr. Daniel William David Hartley
Group General Counsel & Company Secretary
-
Ms. Alison Jane Henriksen
Executive Director, Chief Financial Officer
-
Mr. Jorgen Kokke
Executive Director, Chief Executive Officer
-
Mr. Stephen David Wilson
Executive Director
-

Top 5 shareholders

No. of shares
Wellington Management Company LLP2,672,529
Capital Research and Management Company2,229,203
Jupiter Unit Trust Managers Ltd2,224,009
European Opportunities Trust2,224,009
Royal London Asset Management Ltd2,124,531

Director dealings

Action
28 Feb 2025Exercise of Option
28 Feb 2025Sale of Option
16 Sep 2024Sale of Option
16 Sep 2024Exercise of Option
16 Sep 2024Sale of Option
16 Sep 2024Exercise of Option
06 Sep 2024Purchase
05 Sep 2024Purchase
05 Sep 2024Purchase
05 Sep 2024Purchase
05 Sep 2024Purchase
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.